spacer
home > ebr > current issue
PUBLICATIONS

European Biopharmaceutical Review

ebr
Autumn 2019

   
Text
PDF
bullet
In Brief
In Brief

Vax Populi

EBR’s Industry Advisor, Emile Bellott, discusses the health achievement of vaccinations against infectious diseases in the post-industrial era, and how immunisation is essential to continue saving millions of lives every year.

 
view
download pdf
bullet
Features
Anti-Idiotypic Antibodies

Robust Method Development for Biologics and Biosimilars

Amanda Turner at Bio-Rad Laboratories examines the factors that enable the demand for biological medicines to evolve and expand, such as the introduction of lower-cost biosimilars, or the ongoing identification of new drug targets.

 
view
download pdf
Preclinical Oncological Research

PET Technology and Tumour Progression

Dr Todd Sasser at Bruker BioSpin writes on how, with the advancements of PET scanning, oncologists are now better able to understand the development of cancers and tumours by better highlighting their morphology and other biomarkers.

 
view
download pdf
Accelerating Process Development

Simply Good Monitoring

Paul Kroll and Alexandra Hofer at Securecell AG articulate how digitisation can accelerate process development in relation to the analysis of liquid samples.
 
view
download pdf
High-Productivity Membrane Chromatography

The Next-Generation Purification of Monoclonal Antibodies

Gary Skarja at Merck examines the key developments in mAb manufacturing, including the benefits that address productivity and cost challenges in a singleuse format.

 
view
download pdf
Challenges in Cellular, Tissue, and Gene Therapy Products

Drug Development Decisions

Cost control in drug development is always at the forefront of manufacturer’s minds, and Zeb Younes and Zaklina Buljovcic at PharmaLex examine how automation and decentralising the manufacturing process can help achieve this goal in the long run.
 
view
download pdf
Developments in Artificial Intelligence

Focusing on Target Safety

Although in its infancy, Ruth Roberts at ApconiX describes how artificial intelligence can help reduce the cost and the amount of product failures in regard to drug development and creation.
 
view
download pdf
Standardising Conditions for Extractables Testing

Exhaustive Extraction

Simone Carrara and Michele Vasso at Eurofins illustrate the importance of extractables and leachables to ensure drug efficacy, and that the product remains in optimal condition to interact with the patient.
 
view
download pdf
bullet
Stem Cell Research
Stem Cell Therapy

Recombinant Human Albumin

Cryopreservation and stem cell therapies are facing major changes and advancements, Dr Phil Morton and Dr Daniel Shelly at Albumedix discuss how albumin is useful across the cell therapy value chain.
 
view
download pdf
Live Cell Transport

The Rising Star

The way in which we transport existing cell shipments is continuously being optimised, and Dr Corné Swart at Cellbox Solutions looks into these new devices that allow cells to survive compared to traditional methods.
 
view
download pdf
bullet
Rare Diseases
Orphan Drugs and Rare Diseases

Patient Voices in the Industry

When considering the development of orphan drugs, the patients that suffer from the diseases and help process drug development in clinical trials also have to be considered, write William C Maier and Kelly Franchetti at ICON.
 
view
download pdf
bullet
DNA and RNA Sequencing
Biopharmaceutical Applications

The Advantages of Long-Read Sequencing

Jonas Korlach at Pacific Biosciences discusses the improvements in long-read sequencing technology, and the applications it may have in the discovery of new drugs.
 
view
download pdf
Advances in Oncology

Advancing Liquid Biopsies

Mark Li at Resolution Bioscience examines why liquid biopsies are now becoming more commonly used compared to tissue biopsies.
 
view
download pdf
bullet
Cannabis-Based Drugs
The Potential of Medical Cannabis

Budding Opportunities for Pharma

Shifting attitudes towards cannabis-based medicines are making them more appealing to drug developers, which will in turn help patients who need these drugs, writes Callum McGuinn at Mewburn Ellis.
 
view
download pdf
The Future of Clinical Research on Medical Cannabis

Trial by Fire

Dr Mark A Ware at Canopy Growth Corporation describes the changes in drug policy in recent times surrounding cannabis-based drugs, and the advantages they may have in treating patients.
 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July, and October

News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

White Papers

Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement